Personalized DC Vaccines in Non Small Cell Lung Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 22, 2022

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Non-small Cell Lung Cancer
Interventions
BIOLOGICAL

Autologous dendritic cell vaccine loaded with personalized peptides (PEP-DC vaccine)

"Patients will receive six DC vaccinations Q3W (±3 days) in combination with low dose cyclophosphamide the day before vaccination.~Each dose of vaccine (PEP-DC) will be split into two injections, which will be administered on W2D2 of each cycle, subcutaneously. Patients will be vaccinated until vaccine exhaustion, disease progression, major toxicity or patient withdrawal, whichever is earlier. Additional DC vaccines may be administered Q3W (±3 days) if available until vaccine exhaustion or disease progression, whichever is earlier."

DRUG

Low dose cyclophosphamide

Patients will receive six DC vaccinations Q3W (±3 days) in combination with low dose cyclophosphamide the day before vaccination.

Trial Locations (1)

1011

CHUV Oncology Department, Lausanne

All Listed Sponsors
lead

Centre Hospitalier Universitaire Vaudois

OTHER